Holen Sie sich die Stockscreener-App
1.99
1.00%
-0.02
Xenetic Biosciences Inc Aktie (XBIO) Neueste Nachrichten
Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire
Xenetic partner doses first patient in DNase CAR T-cell study - Investing.com India
Xenetic Biosciences doses first patient in DNase and CAR T-cell study - StreetInsider
Xenetic Biosciences, Inc. (XBIO) Stock Price, News, Quote & History - Yahoo Finance
Form 8K Xenetic Biosciences Inc For: 23 September - Investing.com India
Form 8K Xenetic Biosciences Inc For: 23 September By Investing.com - Investing.com UK
Santersus holders could own about 85% of the combined company in Xenetic Biosciences (XBIO)'s pending exchange. - Stock Titan
Xenetic to acquire Santersus in NET-targeting biotech combination - AllSci
Dig: Santersus Xenetic Sep MERGER premature — close ~Q4 2026 - Dealroom
Xenetic Biosciences (XBIO) investor reports 0% holding - Stock Titan
Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake - Yahoo Finance
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition - Benzinga
Xenetic Biosciences to Merge With Santersus in All-Stock Deal - Minichart
Form 8K Xenetic Biosciences Inc For: 16 September By Investing.com - Investing.com Nigeria
[SUPERSEDED by Dig 154759] Xenetic to merge with Santersus, ceding 85% of combined biotech to Swiss investors - Dealroom.co
Xenetic Biosciences to Acquire Santersus in All-Stock NET Therapeutics Deal - citybiz
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Xenetic Biosciences to acquire Santersus in all-stock deal By Investing.com - Investing.com Nigeria
Xenetic Biosciences to acquire Santersus in all-stock deal By Investing.com - Investing.com Australia
XBIO Looks 12.4% Overvalued on GF Value™ as Market Prices in Hig - GuruFocus
Form 8K Xenetic Biosciences Inc For: 16 September By Investing.com - Investing.com India
Form 8K Xenetic Biosciences Inc For: 16 September By Investing.com - Investing.com UK
Xenetic Biosciences to acquire Santersus in all-stock deal By Investing.com - Investing.com Canada
Xenetic Biosciences to acquire Santersus in all-stock deal - Investing.com
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics - ACCESS Newswire
Santersus deal would leave Xenetic Biosciences (NASDAQ: XBIO) owners with 15% - Stock Titan
Xenetic Biosciences, Inc. (NASDAQ:XBIO) To Acquire Santersus In All-Stock Deal - TradingView
A planned biotech deal would unite four clinical programs around one disease driver - Stock Titan
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition - Yahoo Finance
Xenetic Biosciences, Inc. (NASDAQ:XBIO) To Acquire Santersus in All-Stock Deal; New Ticker 'SNTS' Planned - TradingView
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics - Yahoo Finance
Xenetic Biosciences and Santersus AG agree to create a global leader in therapies against NETs - Demócrata
Xenetic Biosciences Inc. Warrants (XBIOW) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Xenetic Biosciences Inc. Warrants (XBIOW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Xenetic Biosciences Inc. Warrants (XBIOW) Peer Comparison – Compare with Others - Value Research
Xenetic Biosciences Inc. Warrants (XBIOW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Xenetic Biosciences, Inc. Revenue Breakdown – NASDAQ:XBIO - TradingView
XBIO Q2 2025 Earnings: Narrower-Than-Expected Loss of -$0.45 Beats Estimates by 31.07%Financial Health Score - vinanet.vn
Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicense - TradingView
Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss - TradingView
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform - Yahoo Finance
Xenetic Biosciences: Q2 Earnings Snapshot - marketscreener.com
Xenetic Biosciences: Q2 Earnings Snapshot - AOL.com
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform - ACCESS Newswire
Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary - tradingview.com
Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary - TradingView
Xenetic Biosciences (XBIO) Rises 3.31% to $2.81, Approaching Key Resistance at $2.95TWAP Entry - dars.gov.et
Xenetic Biosciences (XBIO) Rises 3.31% to $2.81, Approaching Key Resistance at $2.95Earnings Quality Factor - vinanet.vn
XBIO Q2 2025 Earnings: Narrower Loss of $0.45 per Share Beats Estimates Despite No RevenueEarnings Surprise Stocks - vinanet.vn
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - dars.gov.et
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):